Elutia Inc. (ELUT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Elutia Inc. is a commercial-stage company developing proprietary drug-eluting biomatrix products for surgical reconstruction. The company operates in two segments: Women's Health and Cardiovascular. Following the October 2025 divestiture of its Cardiac Implantable Electronic Device (CIED) business to Boston Scientific and Cardiac Pacemakers, the company is now focused on advancing its next-generation drug-eluting biomatrix platform (NXT-41 and NXT-41x) and commercializing its remaining portfolio (SimpliDerm, ProxiCor, VasCure, Tyke).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $3.11 million | $2.95 million |
| Gross Profit | $1.80 million | $1.38 million |
| Gross Margin | 57.9% | 46.8% |
| Net Loss | $(7.47) million | $(3.93) million |
| Net Loss Per Share (Diluted) | $(0.17) | $(0.21) |
| Cash and Cash Equivalents | $28.49 million | $17.36 million |
| Operating Cash Flow | $(7.83) million | $(8.88) million |
| Total Debt (Revenue Interest Obligation) | $7.37 million | $7.23 million |
Note: The company has no long-term bank debt following the full repayment of its SWK Loan Facility in October 2025 using proceeds from the CIED divestiture.
Material Changes vs. Prior Period
- Revenue Mix Shift: Net sales increased 5.5% year-over-year. Cardiovascular sales surged 214.4% to $1.03 million due to the termination of the LeMaitre Vascular distribution agreement and a shift to direct sales at higher end-user pricing. Conversely, Women's Health sales declined 20.4% to $2.09 million following the termination of the Tiger Aesthetics distribution agreement in October 2025.
- Margin Expansion: Gross margin improved to 57.9% from 46.8%, driven by the shift to direct sales channels which yield higher margins than distributor contracts.
- Expense Volatility:
- R&D: Increased 126.5% to $1.97 million due to aggressive development of NXT-41 and NXT-41x.
- Litigation Costs: Decreased 76.4% to $0.61 million as FiberCel litigation settlements were largely resolved and insurance recoveries offset VBM costs.
- Warrant Liability: The company recorded a $1.66 million loss on the revaluation of warrant liabilities, compared to a $5.19 million gain in the prior year.
- Discontinued Operations: The company recognized a $0.43 million gain from discontinued operations in Q1 2026, primarily from the resolution of an indemnity holdback related to the 2023 Orthobiologics divestiture.
Outlook, Risks, and Contingencies
- Liquidity: Management believes current cash resources ($28.5 million) are sufficient to fund operations for at least 12 months. However, the company expects to incur operating losses for the foreseeable future as it advances product development.
- Product Development: The primary strategic focus is the development and FDA clearance of NXT-41 and NXT-41x, next-generation biologic scaffolds with local antibiotic delivery.
- Legal Contingencies:
- FiberCel Litigation: 105 of 110 cases settled; 4 remain active. A liability of $3.6 million is accrued. No insurance coverage remains for this matter.
- VBM Litigation: 17 of 28 cases settled; 10 remain active. A liability of $4.4 million is accrued. Insurance coverage remains available for future costs.
- Other Litigation: Ongoing disputes with Medtronic (breach of supply agreement), Tiger Aesthetics (distribution agreement), and a former supplier. Management does not currently consider losses probable or estimable for these matters.
- Revenue Interest Obligation: The company owes Ligand Pharmaceuticals 5% of future sales of specific cardiovascular products, subject to annual minimum payments of $4.4 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $28.5 million cash balance against the projected burn rate for NXT-41/41x development and ongoing litigation defense.
- Litigation Exposure: Monitor the status of the 4 active FiberCel cases and 10 active VBM cases, specifically regarding potential liabilities exceeding the current $8.0 million accrual.
- Revenue Sustainability: Assess the long-term impact of losing the Tiger Aesthetics distribution channel on Women's Health revenue and the stability of the new direct sales model for Cardiovascular products.
- Warrant Liability: Track the fair value of outstanding prefunded warrants, as fluctuations in stock price directly impact net income/loss via revaluation charges.
- Regulatory Milestones: Confirm timelines for FDA clearance of NXT-41 and NXT-41x, which are critical for future growth.